|
|
Vaccine Detail
|
SARS-CoV rVV-SARS-N |
| Vaccine Information |
- Vaccine Name: SARS-CoV rVV-SARS-N
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: N protein (Zhao et al., 2016)
- Immunization Route: intranasal immunization
- Description: recombinant vaccinia virus expressing the N protein (rVV-SARS-N)
|
| Host Response |
|
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: Mice were vaccinated with rVV-SARS-N i.n. and boosted 6–7 weeks later.
- Immune Response: Production of N-specific CD4+ T cells, Production of IFN-γ, Production of IL-10, Increased mobilization of CD8+ cells to infected lung. (Zhao et al., 2016)
- Efficacy: protected (Zhao et al., 2016)
|
| References |
Zhao et al., 2016: Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6); 1379-1391. [PubMed: 27287409].
|
|
